Generic Name and Formulations:
Acyclovir 5% + hydrocortisone 1%; crm.
Bausch Health Companies Inc.
Indications for XERESE:
Early treatment of recurrent herpes labialis (cold sores), to reduce likelihood of ulcerative cold sores and shorten lesion healing time in adults and adolescents (≥12yrs old).
Start as soon as possible after the first signs/symptoms emerge (ie, during the prodrome or when lesions appear). Wash and dry area. Apply topically to affected area on lips or around the mouth 5 times daily for 5 days. Avoid unnecessary rubbing of affected area to avoid aggravating or transferring infection. Do not occlude. Wash hands before and after application; wait at least 30 minutes before bathing, showering, or swimming.
Immunocompromised. Reevaluate if symptoms persist more than 2 weeks. Avoid eyes, inside the mouth or nose, or on the genitals. Pregnancy (Cat. B). Nursing mothers.
Antiviral + antiinflammatory.
Do not apply other products (makeup, sunscreen, lip balm, etc) to area during treatment.
Drying, flaking, burning/tingling sensation, erythema, pigmentation changes.
Sign Up for Free e-newsletters
Regimen and Drug Listings
GET FULL LISTINGS OF TREATMENT Regimens and Drug INFORMATION
|Head and Neck Cancer||Regimens||Drugs|
|Renal Cell Carcinoma||Regimens||Drugs|
Cancer Therapy Advisor Articles
- Genetic Counseling Recommended for Advanced Prostate Cancer
- BRCA1/Shieldin Double Mutations May Signal Resistance to PARP Inhibitors
- Study Analyzing Postmarketing Data on Breast Implant Safety Sparks FDA Response
- Higher-Dose Immunoglobulin Replacement Therapy in Chronic Lymphocytic Leukemia
- Beyond BRCA: New Predisposition Genes Linked to Breast, Ovarian Cancers
- Despite Promising Trial Results, Skeptics Raise Red Flags About Anlotinib's Efficacy in Heavily Treated NSCLC
- Higher Risk of MGUS in Relatives of Patients With Multiple Myeloma Confirmed
- Brentuximab Vedotin Combo Active in Older Patients With Hodgkin Lymphoma
- Prostate Cancer Drug Resistance Mediated by Epigenetic Changes
- Nilotinib and Dasatinib Confer Similar Outcomes for Chronic-Phase CML